Intercept Pharmaceuticals Reports That New Data From Interim Analysis Of REGENERATE Show That OCA Helped Patients With Liver Fibrosis Due To NASH Achieve Sustained Improvement In Noninvasive Markers Of Fibrosis Over Two Years Of Treatment